

2

PD1294-SD

new matter has been added. Applicants representative, Lisa A. Tumarkin, had a telephone conversation with the Examiner, Lorraine Spector, on July 1, 1994 regarding the Amendment filed on June 20, 1994 in the above-identified patent application. Ms. Spector had several suggestions in order to place the application in better form for allowance.

The Examiner requested resubmission of the inventor's declaration originally submitted on June 20, 1994, signed by Dr. Gary Groten-dorst. As requested, Applicants have submitted a new declaration under 37 CFR §1.132, which is now signed by all of the inventors. In addition, Applicants have submitted a new abstract. Applicants wish to thank the Examiner for her time and helpful suggestions. Applicants respectfully request reconsideration of the present application.

IN THE CLAIMS

Please amend the claims as follows:

In claim 1, lines 2 and 3, please delete "or fragments thereof".

IN THE SPECIFICATION


Please delete the abstract and substitute the following abstract:
--A novel chemotactic and mitogenic protein, Connective Tissue Growth Factor (CTGF), a polynucleotide that encodes CTGF and antibodies that bind to CTGF are provided. Diagnostic and therapeutic methods using CTGF are also described.--

In summary, based on Applicants' comments above, it is respectfully submitted that claims 1 and 14-16 clearly and patentably define the invention. Applicants respectfully request that the Examiner reconsider the various grounds of rejection set forth in the Office Action and, in light of Applicants' additional amendments, allow the claims now pending to proceed to issuance.

Respectively submitted,

SPENSLEY HORN JUBAS & LUBITZ

Dated: 7/5/94


Lisa A. Tumarkin, Ph.D.
Reg. No. P-38,347

1880 Century Park East
Fifth Floor
Los Angeles, CA 90067
(619) 455-5100
LAT/dn